

1 **Multimorbidity and blood pressure control: a cross-sectional analysis among 67,385 adults with**  
2 **hypertension in Canada**

3 Short title: Multimorbidity and blood pressure control in primary care

4 Tu N Nguyen <sup>1,2</sup>, Sumeet Kalia <sup>2</sup>, Peter Hanlon <sup>3</sup>, Bhautesh D Jani <sup>3</sup>, Barbara I Nicholl <sup>3</sup>, Chelsea D.  
5 Christie <sup>2</sup>, Babak Aliarzadeh <sup>2</sup>, Rahim Moineddin <sup>2</sup>, Christopher Harrison <sup>4</sup>, Clara Chow <sup>1</sup>, Martin  
6 Fortin <sup>5</sup>, Frances S Mair <sup>3</sup>, Michelle Greiver <sup>2,6</sup>

7

8 <sup>1</sup> Westmead Applied Research Centre, Sydney Medical School, Faculty of Medicine and Health,  
9 University of Sydney, Sydney, New South Wales, Australia.

10 <sup>2</sup> Department of Family and Community Medicine, Temerty Faculty of Medicine, University of  
11 Toronto, Toronto, ON, Canada

12 <sup>3</sup> General Practice and Primary Care, School of Health and Wellbeing, University of Glasgow, UK

13 <sup>4</sup> Menzies Centre for Health Policy and Economics, School of Public Health, Faculty of Medicine and  
14 Health, University of Sydney, Sydney, New South Wales, Australia

15 <sup>5</sup> Department of family medicine and emergency medicine, Université de Sherbrooke, Saguenay, QC,  
16 Canada

17 <sup>6</sup> Department of Family and Community Medicine, North York General Hospital, Toronto, ON,  
18 Canada

19

20

21

22

23

24

25 **Abstract**

26 **Background.** There has been conflicting evidence on the association between multimorbidity and  
27 blood pressure (BP) control. This study aimed to investigate this associations in people with  
28 hypertension attending primary care in Canada, and to assess whether individual long-term conditions  
29 are associated with BP control.

30 **Methods.** A cross-sectional study in people with hypertension attending primary care in Toronto  
31 between January 01 2017 and December 31 2019. Uncontrolled BP was defined as systolic BP $\geq$ 140  
32 mmHg or diastolic BP $\geq$ 90 mmHg. A list of 11 a priori selected chronic conditions was used to define  
33 multimorbidity. Multimorbidity was defined as having  $\geq$ 1 long-term condition in addition to  
34 hypertension. Logistic regression models were used to estimate the association between  
35 multimorbidity (or individual long-term conditions) with uncontrolled BP.

36 **Results.** A total of 67,385 patients with hypertension were included. They had a mean age of 70,  
37 53.1% were female, 80.6% had multimorbidity, and 35.7% had uncontrolled BP. Patients with  
38 multimorbidity had lower odds of uncontrolled BP than those without multimorbidity (adjusted OR  
39 0.72, 95% CI 0.68-0.76). Among the long-term conditions, diabetes (aOR 0.73, 95%CI 0.70-0.77),  
40 heart failure (aOR 0.81, 95%CI 0.73-0.91), ischemic heart disease (aOR 0.74, 95%CI 0.69-0.79),  
41 schizophrenia (aOR 0.79, 95%CI 0.65-0.97), depression/anxiety (aOR 0.91, 95%CI 0.86-0.95),  
42 dementia (aOR 0.87, 95%CI 0.80-0.95), and osteoarthritis (aOR 0.89, 95%CI 0.85-0.93) were  
43 associated with a lower likelihood of uncontrolled BP.

44 **Conclusion.** We found that multimorbidity was associated with better BP control. Several conditions  
45 were associated with better control, including diabetes, heart failure, ischemic heart disease,  
46 schizophrenia, depression/anxiety, dementia, and osteoarthritis.

47 Keywords: hypertension, high blood pressure, blood pressure control, multimorbidity, primary care

48

## 49 **Introduction**

50 Hypertension is a risk factor for cardiovascular disease and other chronic health conditions. The  
51 prevalence of hypertension increases with age, with a prevalence of only 27% in people younger than  
52 60 years, but 74% in people aged 80 and older.<sup>1</sup> Globally, blood pressure (BP) control is still  
53 suboptimal, with control rates of only approximately 20% for people with hypertension.<sup>2</sup> Poor control  
54 of hypertension can increase the risk of heart failure, coronary heart disease, peripheral artery disease,  
55 renal failure, stroke and dementia, and therefore, increase the risk of developing multimorbidity in  
56 people with hypertension.<sup>3</sup> Multimorbidity, defined as having two or more chronic conditions, has  
57 become a primary healthcare concern.<sup>4,5</sup>

58 Two out of three people with hypertension have additional long-term condition.<sup>6</sup> A systematic  
59 review of 45 studies conducted from 2007 to 2017 showed that the overall prevalence of  
60 multimorbidity was 66.1% (when multimorbidity was defined as having  $\geq 2$  chronic conditions), and  
61 44.2% (when multimorbidity was defined as having  $\geq 3$  chronic conditions) in older adults in high-  
62 income countries.<sup>7</sup> In the United States, 81 million adults were estimated to have multimorbidity in  
63 2020.<sup>8</sup> In Canada, the prevalence of multimorbidity is also high, with a reported prevalence ranging  
64 from around 30% to 70% in primary care settings, and around 17% to 59% in the general population.<sup>9</sup>  
65 Multimorbidity increases healthcare costs and healthcare utilisation including hospitalisations.<sup>10,11</sup>

66 Several studies have examined the impact of multimorbidity on BP control, and there has been  
67 conflicting evidence on the association between multimorbidity and hypertension control.<sup>12-17</sup> While  
68 some studies show that the presence of multimorbidity was positively associated with BP  
69 control,<sup>12,16,18</sup> other studies suggested that people with more comorbidities had poorer management  
70 and control of hypertension.<sup>15,17</sup> There is minimal evidence of this association in the Canadian  
71 population. Therefore, in this study, we aimed to investigate the association between multimorbidity  
72 and BP control in patients attending primary care in Canada, and to assess if individual comorbidities  
73 are associated with BP control.

74

## 75 **Materials and Methods**

### 76 *Data source*

77 This study used data from the University of Toronto Practice-Based Research Network (UTOPIAN),  
78 a primary care electronic medical records (EMRs) database. The UTOPIAN database contains de-  
79 identified records from participating family medicine clinics in Ontario, Canada, with most providers  
80 practicing in the Greater Toronto Area.<sup>19</sup> Data include de-identified patient-level information on  
81 various factors including demographics, medical diagnoses, procedures, medications, immunizations,  
82 laboratory test results, vital signs, risk factors, and clinical notes.

### 83 *Study design and eligible patients*

84 This is a cross-sectional study using the UTOPIAN 2021Q4 database with a start date of January 01  
85 2017 and an end date of December 31 2019. This end date was chosen to avoid the COVID-19  
86 pandemic-related effects on the data. The data were accessed for research purposes from June 17 2022  
87 to December 16 2022. We identified a cohort of patients who met the following selection criteria; had  
88 hypertension before December 31 2019; had blood pressure recorded between Jan 01 2017 and Dec  
89 31 2019; and were at least 45 years old when their blood pressure was measured. **Figure 1** provides a  
90 flowchart for the cross-sectional cohort.

91 We defined the hypertension phenotype using the following criteria (Appendix 2):

- 92 1. Free text documentation of hypertension was found within the (past or present) health  
93 condition section of the cumulative patient profile, including the following terms:  
94 hypertension, hypertensive, htn; OR
- 95 2. Anti-hypertensive medication was prescribed and an elevated blood pressure reading was  
96 recorded at any point in the EMR (elevated blood pressure reading is defined as systolic blood  
97 pressure  $\geq$  140 mmHg or diastolic blood pressure  $\geq$  90 mmHg); OR
- 98 3. Anti-hypertensive medication was prescribed and a billing record with the diagnosis code for  
99 hypertension (ICD-9 code 401) was recorded at any point in the EMR; OR

100 4. A billing record with the diagnosis code for hypertension (ICD-9 code 401) and an elevated  
101 blood pressure reading was recorded at any point in the EMR (elevated blood pressure  
102 reading is defined as systolic blood pressure  $\geq$  140 mmHg or diastolic blood pressure  $\geq$  90  
103 mmHg)

#### 104 *Multimorbidity*

105 Multimorbidity was defined as having one or more long-term conditions in addition to hypertension.  
106 This definition of multimorbidity is similar to definitions used in other studies (REFs).<sup>20-22</sup> A list of 11  
107 a priori selected chronic conditions was used to define multimorbidity, in alignment with the Centers  
108 for Disease Control and Prevention (CDC) recommendations for defining and measuring multiple  
109 chronic conditions when using Medicare claims.<sup>23</sup> These long-term conditions are: ischemic heart  
110 disease, heart failure, atrial fibrillation, diabetes, chronic obstructive pulmonary disease, asthma,  
111 chronic kidney disease (chronic kidney disease stage 3 or more, or dependence on transplant or  
112 dialysis), cancers (including breast cancer, cervical cancer, lung cancer, colorectal cancer, ovarian  
113 cancer, pancreatic cancer, prostate cancer, thyroid cancer), osteoarthritis, dementia, depression and/or  
114 anxiety, and schizophrenia.

#### 115 *Covariate definitions*

116 We used the most recent information on Body Mass Index (BMI) and smoking status as of December  
117 31, 2019. BMI was grouped into underweight ( $\leq$ 18.4), normal (18.5-24.9), overweight (25.0-29.9),  
118 obese class I (30.0-34.9), obese class II (35.0-39.9), and obese class III ( $\geq$ 40.0). We calculated age (in  
119 years) on the date when the blood pressure measurement was recorded between January 01, 2017 and  
120 December 31, 2019. We used rurality and neighbourhood income quintiles (as an indicator of  
121 socioeconomic status) using data from the 2016 Statistics Canada Census.<sup>24</sup>

122 We identified different classes of hypertension medication (including angiotensin converting enzyme  
123 inhibitors (ACEi), angiotensin II receptor blocker (ARBi), calcium channels, beta-blockers, diuretics,  
124 and other classes of hypertension medication) that were prescribed during the six months prior to the  
125 blood pressure measurement. The full description of drug names for each class of hypertension

126 medication is provided in Appendix section (i), along with the algorithm used to determine the  
127 presence of hypertension in EMRs (see Appendix section (ii)).

#### 128 *Outcome measure*

129 The primary outcome measurement was the most recent BP measure recorded during the study period  
130 (January 01, 2017 to December 31, 2019). Uncontrolled BP was defined as having either systolic  
131 blood pressure  $\geq 140$  mmHg or diastolic blood pressure  $\geq 90$  mmHg for the last BP measurement prior  
132 to December 31 2019. The BP treatment target was chosen to align with the Hypertension Canada's  
133 2016 Canadian hypertension education program guidelines for blood pressure measurement,  
134 diagnosis, assessment of risk, prevention, and treatment of hypertension that reflected the practice  
135 during the study period.<sup>25</sup> The SBP treatment goal is a pressure level of  $< 140$  mm Hg (Grade C). The  
136 DBP treatment goal is a pressure level of  $< 90$  mm Hg (Grade A). These targets were established  
137 using Office-based BP Measurements (OBPM).<sup>25</sup> For patients with multiple BP readings recorded on  
138 the same day at the same visit (e.g. using an automated BPtru machine), we took the average  
139 measurement of the systolic and diastolic blood pressure measures on that day.

140 We also conducted a sensitivity analysis, with a BP target of  $< 130/80$  mmHg, as recommended by  
141 the 2018 ESC/ESH Guidelines for the management of arterial hypertension<sup>26</sup>, and the 2017  
142 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention,  
143 Detection, Evaluation, and Management of High Blood Pressure in Adults.<sup>27</sup>

#### 144 *Statistical analysis*

145 We used descriptive statistics to summarize patient demographics and clinical characteristics  
146 associated with controlled and uncontrolled blood pressure. We used means, standard deviations, and  
147 median, minimum and maximum to summarize continuous variables, while frequencies and  
148 percentages were used to summarize categorical variables. To reduce the risk of re-identification, our  
149 reports exclude any cell count of five or fewer. Comparisons between patients with controlled and  
150 uncontrolled BP were assessed using Pearson chi-square tests for categorical covariates and using  
151 two-sample t-tests for continuous covariates.

152 We fitted logistic regression models using the Generalized Estimating Equations (GEE) with an  
153 exchangeable working correlation matrix to assess the association between multimorbidity (or  
154 individual long-term condition) on uncontrolled BP. We reported both the unadjusted odds ratios and  
155 adjusted odds ratios. To account for multicollinearity, we fitted separate logistic models using GEE  
156 for multimorbidity and different comorbidities, respectively. We a priori specified age, sex, income  
157 quintiles, smoking BMI as potential confounders (i.e. common cause) for multimorbidity and for the  
158 outcome of BP control, while different classes of hypertension medications were considered potential  
159 mediators on the pathway between multimorbidity and BP control (see Supplementary Figure S1). In  
160 GEE models, we adjusted for the following covariates: age, sex, income quintiles, smoking status,  
161 BMI, number of primary care visits, along with the multimorbidity status.

162 In a sensitivity analysis, we used a reduced threshold for blood pressure control (<130/80 mm Hg) and  
163 excluded BMI and smoking status in the regression models to include patients that did not have BMI  
164 or smoking status recorded.

#### 165 *Ethics approval*

166 This study was approved by the Research Ethics Board at the University of Toronto (protocol number  
167 00043354).

## 168 **Results**

### 169 *Sample characteristics*

170 A total of 67,385 patients who satisfied the selection criteria were included in this study. Patients in  
171 the sample had a mean age of 70.1 years (SD 11.8) and 53.1% were female. The prevalence of  
172 overweight and obesity was 66%, with a greater proportion of patients with class II and class III  
173 obesity in the uncontrolled BP group compared to the controlled BP group. There was no difference in  
174 socioeconomic status between the two groups. (**Table 1**)

### 175 *Multimorbidity*

176 The overall prevalence of multimorbidity was 80.6%. Patients with multimorbidity had a higher  
177 number of annual primary care visits than patients without multimorbidity in 2017, 2018 and 2019  
178 (**Supplementary Table S2**). As an example, 8.0% of the patients with multimorbidity had more than  
179 9 visits in 2019 compared to 1.9% of patients without multimorbidity

#### 180 *Uncontrolled blood pressure*

181 Overall, 35.7% of patients had uncontrolled BP (34.1% in patients with multimorbidity and 42.7% in  
182 patients without multimorbidity,  $p < 0.001$ ). **Figure 2** presents the percentages of uncontrolled BP in  
183 patients with and without multimorbidity. Across the three age groups, patients with multimorbidity  
184 had lower rates of uncontrolled BP compared to patients without multimorbidity.

#### 185 *The association between multimorbidity and hypertension control*

186 Patients with multimorbidity had lower odds of uncontrolled BP compared to those without  
187 multimorbidity (adjusted OR = 0.72, 95% CI 0.68 to 0.76, adjusted for age, sex, income quintiles,  
188 smoking status, body mass index, and number of visits). Younger patients had lower odds of having  
189 uncontrolled BP than older patients. Obese patients (in class I, II and III) had higher odds of  
190 uncontrolled BP than those with normal BMI. Current smokers had higher odds of having  
191 uncontrolled BP compared to non-smokers. Increasing number of visits to primary care doctors was  
192 associated with lower odds of uncontrolled BP. (**Figure 3**)

193

#### 194 *The association between types of long-term conditions and hypertension control*

195 Among the long-term conditions, seven conditions were significantly associated with lower likelihood  
196 of uncontrolled BP: diabetes (adjusted OR 0.73, 95%CI 0.70-0.77), heart failure (adjusted OR 0.81,  
197 95%CI 0.73-0.91), ischemic heart disease (adjusted OR 0.74, 95%CI 0.69-0.79), schizophrenia  
198 (adjusted OR 0.79, 95%CI 0.65-0.97), depression/anxiety (adjusted OR 0.91, 95%CI 0.86-0.95),  
199 dementia (adjusted OR 0.87, 95%CI 0.80-0.95), and osteoarthritis (adjusted OR 0.89, 95%CI 0.85-



200 0.93). The remaining long-term conditions (atrial fibrillation, COPD, asthma, chronic kidney disease,  
201 and cancer) were not associated with uncontrolled BP. (**Figure 4**)

202

203 *Sensitivity analysis*

204 Sensitivity analyses showed consistent results (**Supplementary Tables S3, S4**).

205 In GEE models using  $\geq 130/80$  mmHg as the threshold for sub-optimal blood pressure control,  
206 multimorbidity was still significantly associated with reduced likelihoods of uncontrolled BP  
207 (adjusted ORs 0.56, 95%CI 0.54-0.59), adjusting for age, sex, income quintiles, body mass index, and  
208 number of visits).

209 **Discussion**

210 *Summary of findings*

211 In this study, we aimed to investigate the association between multimorbidity and uncontrolled BP,  
212 and to assess if individual long-term conditions are associated with uncontrolled BP. Our analysis in  
213 67,385 Canadians aged 45 years or more with hypertension attending primary care from 2017 to 2019  
214 showed an association between the presence of comorbidities and better blood pressure control.  
215 Multimorbidity was associated with approximately 30% lower odds of uncontrolled BP. The  
216 individual long-term conditions that were significantly associated with lower likelihood of  
217 uncontrolled BP include diabetes, heart failure, ischemic heart disease, schizophrenia,  
218 depression/anxiety, dementia, or osteoarthritis.

219 *Comparison to the literature*

220 Our finding aligns with other studies that examined this association, which reported that  
221 multimorbidity was one of the strongest predictors of controlled BP in patients with hypertension.  
222 Tapela and colleagues found that multimorbidity was positively associated with BP control among  
223 participants with hypertension in the UK Biobank, and the types of comorbidities that were  
224 significantly associated with controlled BP included cardiovascular disease (OR 2.11, 95% CI 2.04 to

225 2.19), diabetes (OR 1.32, 95% CI 1.27 to 1.36), migraines (OR 1.68, 95% CI 1.56 to 1.81), and  
226 depression (OR 1.27, 95% CI 1.20 to 1.34).<sup>28</sup> Another study conducted by Sarkar and colleagues in  
227 31,676 patients with hypertension in the Lambeth Data-Net, a patient-level primary care database in  
228 the UK, found that 16,140 (51 %) had multimorbidity, and hypertensive patients with multimorbidity  
229 had lower BP than those with hypertension alone.<sup>12</sup> Mini and colleagues also reported that blood  
230 pressure control was better in participants who reported any comorbidity (OR 2.37, 95%CI 1.51–3.71)  
231 compared to those who did not report any.<sup>16</sup> However, several other studies reported the opposite  
232 findings - people with more comorbidities had poorer management and control of hypertension. In a  
233 study of 223,286 patients with hypertension in Hongkong, Wong et al. found that the proportion of  
234 patients having poor BP control increased from 35.0% to 65.0% and 69.1% when the number of  
235 medical conditions increased from zero to one and two, respectively.<sup>15</sup> However, this study enrolled  
236 adult patients prescribed their first antihypertensive agents; hence people with comorbidities (such as  
237 diabetes, heart failure, coronary heart disease) who were already on a relevant medication (beta-  
238 blockers, ACE inhibitors) for these reasons would be excluded from the hypertension cohort. A cross-  
239 sectional analysis of the World Health Organisation Study of Global Ageing and Adult Health (WHO  
240 SAGE) Wave 1 (2007–10) in 41,557 adults (9778 with hypertension) from 6 middle-income countries  
241 (including China, Ghana, India, Mexico, Russia and South Africa) reported that more comorbidities  
242 were associated with increased odds of uncontrolled hypertension.<sup>17</sup>

243 The BP control rate in our study is also consistent with the literature. In a recent report from the NCD  
244 Risk Factor Collaboration using data from 1990 to 2019 on people aged 30–79 years from population-  
245 representative studies with measurement of blood pressure, the estimated rate of uncontrolled BP in  
246 Canada was 25%-30% in 2019.<sup>29</sup> A report from the Danish General Practice Database of 37,651  
247 patients with hypertension from 231 general practices showed that the overall BP control rate was  
248 33.2%.<sup>18</sup> A cross-sectional population-based study including 99,468 participants with hypertension  
249 enrolled in the UK Biobank reported that the overall control rate of BP was 38.1%.<sup>28</sup>

250 *Implication for practice and research*

251 The results from this study may reflect the achievement of primary care in controlling cardiovascular  
252 risk factors in patients with multimorbidity, including regular BP measures and treatment.  
253 Comorbidities may be associated with more frequent healthcare utilisation and hence increase the  
254 monitoring of chronic conditions, including BP measurement and counselling on lifestyle  
255 modifications and medication adherence. Another explanation could be the study's participation  
256 selection processes. Among people with hypertension as their only chronic health condition, those  
257 with poorer BP control may be more motivated to attend primary care and hence were included in this  
258 cohort. Thus, the observed associations could be explained by selection bias – hypertensive patients  
259 with no comorbidities, but uncontrolled BP may have been more likely to seek primary care compared  
260 to hypertensive patients with no comorbidities and controlled BP. These lead to opportunities to  
261 measure BP and obtain scripts, reminders given to them on taking medications, and better lifestyle  
262 modifications. More studies are needed to explore the mechanisms underlying the associations  
263 between multimorbidity and BP control.

#### 264 *Strengths and limitations*

265 This is one of the largest analyses of hypertension control in adults attending primary care in Canada,  
266 with comprehensive sociodemographic and high-quality detailed clinical information, including  
267 comorbidities. However, the data was only collected from patients in Ontario and is not nationally  
268 representative. Another limitation of this study is that EMR data may be incomplete, and we might be  
269 unable to capture all cases of hypertension and/or prescriptions of anti-hypertensive medications.  
270 Lifestyle modification, which is an essential strategy in the management of hypertension and can  
271 influence BP control, could not be captured through the EMR data. Duration and severity of  
272 hypertension and other chronic diseases were also not captured. Therefore, results should be  
273 replicated and cautiously interpreted before generalizing to all patients in primary care.

#### 274 **Conclusion**

275 In this large-scale study of patients attending primary care with hypertension, multimorbidity was  
276 associated with better BP control. Several long-term conditions were associated with better control,  
277 including diabetes, heart failure, ischemic heart disease, schizophrenia, depression/anxiety, dementia,  
278 and osteoarthritis. Further large-scale mixed methods studies are needed to explore the mechanisms

279 underlying the associations between multimorbidity and BP control, and to understand barriers to BP  
280 control in primary care.

281

282 **Acknowledgements.** Dr Tu Nguyen is supported by the University of Sydney Global Development  
283 Awards.

## 284 **References**

- 285 1. Oliveros E, Patel H, Kyung S, et al. Hypertension in older adults: Assessment, management,  
286 and challenges. *Clinical Cardiology* 2019; **43**: 99-107.
- 287 2. Nguyen TN, Chow CK. Global and national high blood pressure burden and control. *The*  
288 *Lancet* 2021; **398**(10304): 932-3.
- 289 3. Sierra C. Hypertension and the Risk of Dementia. *Front Cardiovasc Med* 2020; **7**: 5-.
- 290 4. Fortin M, Dubois MF, Hudon C, Soubhi H, Almirall J. Multimorbidity and quality of life: a  
291 closer look. *Health and quality of life outcomes* 2007; **5**: 52.
- 292 5. Skou ST, Mair FS, Fortin M, et al. Multimorbidity. *Nat Rev Dis Primers* 2022; **8**(1): 48.
- 293 6. Kennard L, O'Shaughnessy KM. Treating hypertension in patients with medical  
294 comorbidities. *BMJ* 2016; **352**: i101.
- 295 7. Ofori-Asenso R, Chin KL, Curtis AJ, Zomer E, Zoungas S, Liew D. Recent Patterns of  
296 Multimorbidity Among Older Adults in High-Income Countries. *Popul Health Manag* 2018.
- 297 8. Vogeli C, Shields AE, Lee TA, et al. Multiple chronic conditions: prevalence, health  
298 consequences, and implications for quality, care management, and costs. *Journal of general internal*  
299 *medicine* 2007; **22 Suppl 3**: 391-5.
- 300 9. Mokraoui NM, Haggerty J, Almirall J, Fortin M. Prevalence of self-reported multimorbidity  
301 in the general population and in primary care practices: a cross-sectional study. *BMC Res Notes* 2016;  
302 **9**: 314.
- 303 10. Marina S-B, Mark A, Alessandra B, et al. Impact of multimorbidity on healthcare costs and  
304 utilisation: a systematic review of the UK literature. *British Journal of General Practice* 2021;  
305 **71**(702): e39.

- 306 11. Rodrigues LP, de Oliveira Rezende AT, Delpino FM, et al. Association between  
307 multimorbidity and hospitalization in older adults: systematic review and meta-analysis. *Age and*  
308 *Ageing* 2022; **51**(7): afac155.
- 309 12. Sarkar C, Dodhia H, Crompton J, et al. Hypertension: a cross-sectional study of the role of  
310 multimorbidity in blood pressure control. *BMC family practice* 2015; **16**: 98-.
- 311 13. Paulsen MS, Andersen M, Thomsen JL, et al. Multimorbidity and Blood Pressure Control in  
312 37 651 Hypertensive Patients From Danish General Practice. *Journal of the American Heart*  
313 *Association*; **2**(1): e004531.
- 314 14. Tran J, Norton R, Canoy D, et al. Multi-morbidity and blood pressure trajectories in  
315 hypertensive patients: A multiple landmark cohort study. *PLoS medicine* 2021; **18**(6): e1003674-e.
- 316 15. Wong MC, Wang HH, Cheung CS, et al. Factors associated with multimorbidity and its link  
317 with poor blood pressure control among 223,286 hypertensive patients. *Int J Cardiol* 2014; **177**(1):  
318 202-8.
- 319 16. Mini G, Mohan M, Sarma P, Thankappan K. Multi-morbidity and blood pressure control:  
320 Results of a cross-sectional study among school teachers in Kerala, India. *Indian Journal of Public*  
321 *Health* 2021; **65**(2): 190-3.
- 322 17. Sum G, Koh GC-H, Mercer SW, et al. Patients with more comorbidities have better detection  
323 of chronic conditions, but poorer management and control: findings from six middle-income  
324 countries. *BMC Public Health* 2020; **20**(1): 9.
- 325 18. Paulsen MS, Andersen M, Thomsen JL, et al. Multimorbidity and blood pressure control in  
326 37 651 hypertensive patients from Danish general practice. *J Am Heart Assoc* 2012; **2**(1): e004531.
- 327 19. Tu K, Sodhi S, Kidd M et al. The University of Toronto Family Medicine Report: Caring for  
328 our Diverse Populations. Toronto, ON; 2020.
- 329 20. Sarkar C, Dodhia H, Crompton J, et al. Hypertension: a cross-sectional study of the role of  
330 multimorbidity in blood pressure control. *BMC Family Practice* 2015; **16**(1): 98.
- 331 21. Fortin M, Stewart M, Poitras ME, Almirall J, Maddocks H. A systematic review of  
332 prevalence studies on multimorbidity: toward a more uniform methodology. *Ann Fam Med* 2012;  
333 **10**(2): 142-51.

- 334 22. Kone AP, Mondor L, Maxwell C, Kabir US, Rosella LC, Wodchis WP. Rising burden of  
335 multimorbidity and related socio-demographic factors: a repeated cross-sectional study of Ontarians.  
336 *Can J Public Health* 2021; **112**(4): 737-47.
- 337 23. Goodman RA, Posner SF, Huang ES, Parekh AK, Koh HK. Defining and measuring chronic  
338 conditions: imperatives for research, policy, program, and practice. *Prev Chronic Dis* 2013; **10**: E66.
- 339 24. Statistics Canada. Postal CodeOM Conversion File (PCCF), Reference Guide 2017. .  
340 <https://www150.statcan.gc.ca/n1/pub/92-154-g/92-154-g2017001-eng.htm> (accessed 01/11/2022).
- 341 25. Leung AA, Nerenberg K, Daskalopoulou SS, et al. Hypertension Canada's 2016 Canadian  
342 Hypertension Education Program Guidelines for Blood Pressure Measurement, Diagnosis,  
343 Assessment of Risk, Prevention, and Treatment of Hypertension. *Can J Cardiol* 2016; **32**(5): 569-88.
- 344 26. Williams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of  
345 arterial hypertension. *Eur Heart J* 2018; **39**(33): 3021-104.
- 346 27. Whelton PK, Carey RM, Aronow WS, et al. 2017  
347 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention,  
348 Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American  
349 College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.  
350 *Hypertension* 2018; **71**(6): e13-e115.
- 351 28. Tapela N, Collister J, Clifton L, Turnbull I, Rahimi K, Hunter DJ. Prevalence and  
352 determinants of hypertension control among almost 100 000 treated adults in the UK. *Open Heart*  
353 2021; **8**(1): e001461.
- 354 29. Zhou B, Carrillo-Larco RM, Danaei G, et al. Worldwide trends in hypertension prevalence  
355 and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-  
356 representative studies with 104 million participants. *The Lancet* 2021; **398**(10304): 957-80.

357

358

359

360

361 **Table 1: Patient characteristics**

	<b>Controlled BP</b> (N=43303)	<b>Uncontrolled BP</b> (N=24082)	<b>Overall</b> (N=67385)
<b>Age (years)</b>			
Mean (SD)	70.3 (11.6)	69.6 (12.2)	70.1 (11.8)
Median [Min, Max]	70.0 [47.0, 111]	69.0 [47.0, 110]	70.0 [47.0, 111]
<b>Age group (years)</b>			
45-74 years	30562 (70.6%)	17256 (71.7%)	47818 (71.0%)
75-84 years	8927 (20.6%)	4486 (18.6%)	13413 (19.9%)
85+ years	3814 (8.8%)	2340 (9.7%)	6154 (9.1%)
<b>Sex</b>			
Female	22637 (52.3%)	13132 (54.5%)	35769 (53.1%)
Male	20666 (47.7%)	10950 (45.5%)	31616 (46.9%)
<b>Income Quintiles</b>			
1 (low income)	8984 (20.7%)	5090 (21.1%)	14074 (20.9%)
2	7812 (18.0%)	4328 (18.0%)	12140 (18.0%)
3	7264 (16.8%)	3938 (16.4%)	11202 (16.6%)
4	7572 (17.5%)	4177 (17.3%)	11749 (17.4%)
5 (high income)	10693 (24.7%)	5976 (24.8%)	16669 (24.7%)
Missing	978 (2.3%)	573 (2.4%)	1551 (2.3%)
<b>Multimorbidity</b>			
No	7473 (17.3%)	5574 (23.1%)	13047 (19.4%)

	<b>Controlled BP (N=43303)</b>	<b>Uncontrolled BP (N=24082)</b>	<b>Overall (N=67385)</b>
Yes	35830 (82.7%)	18508 (76.9%)	54338 (80.6%)
<b>Body mass index level</b>			
Missing	7831 (18.1%)	5018 (20.8%)	12849 (19.1%)
18.4 or less (Underweight)	267 (0.6%)	145 (0.6%)	412 (0.6%)
18.5 - 24.9 (Normal)	6453 (14.9%)	3220 (13.4%)	9673 (14.4%)
25 - 29.9 (Overweight)	13470 (31.1%)	6999 (29.1%)	20469 (30.4%)
30 - 34.9 (Obese Class I)	9278 (21.4%)	5095 (21.2%)	14373 (21.3%)
35 - 39.9 (Obese Class II)	3782 (8.7%)	2208 (9.2%)	5990 (8.9%)
40 or more (Obese Class III)	2222 (5.1%)	1397 (5.8%)	3619 (5.4%)
<b>Most recent smoking status</b>			
Missing	11062 (25.5%)	6740 (28.0%)	17802 (26.4%)
Current	4219 (9.7%)	2542 (10.6%)	6761 (10.0%)
Non-Smoker	19999 (46.2%)	10868 (45.1%)	30867 (45.8%)
Past	8023 (18.5%)	3932 (16.3%)	11955 (17.7%)
<b>Cancer</b>			
No	37881 (87.5%)	21349 (88.7%)	59230 (87.9%)
Yes	5422 (12.5%)	2733 (11.3%)	8155 (12.1%)
<b>Ischemic Heart disease</b>			
No	37182 (85.9%)	21679 (90.0%)	58861 (87.4%)
Yes	6121 (14.1%)	2403 (10.0%)	8524 (12.6%)
<b>Heart failure</b>			



	<b>Controlled BP (N=43303)</b>	<b>Uncontrolled BP (N=24082)</b>	<b>Overall (N=67385)</b>
No	40754 (94.1%)	23082 (95.8%)	63836 (94.7%)
Yes	2549 (5.9%)	1000 (4.2%)	3549 (5.3%)
<b>Atrial fibrillation</b>			
No	38362 (88.6%)	21878 (90.8%)	60240 (89.4%)
Yes	4941 (11.4%)	2204 (9.2%)	7145 (10.6%)
<b>Diabetes Mellitus</b>			
No	28126 (65.0%)	17210 (71.5%)	45336 (67.3%)
Yes	15177 (35.0%)	6872 (28.5%)	22049 (32.7%)
<b>Chronic Kidney disease</b>			
No	35292 (81.5%)	20021 (83.1%)	55313 (82.1%)
Yes	8011 (18.5%)	4061 (16.9%)	12072 (17.9%)
<b>Chronic Obstructive Pulmonary Disease</b>			
No	39365 (90.9%)	22197 (92.2%)	61562 (91.4%)
Yes	3938 (9.1%)	1885 (7.8%)	5823 (8.6%)
<b>Osteoarthritis</b>			
No	26654 (61.6%)	15500 (64.4%)	42154 (62.6%)
Yes	16649 (38.4%)	8582 (35.6%)	25231 (37.4%)
<b>Dementia</b>			
No	39774 (91.9%)	22422 (93.1%)	62196 (92.3%)
Yes	3529 (8.1%)	1660 (6.9%)	5189 (7.7%)
<b>Depression and/or Anxiety</b>			

	<b>Controlled BP (N=43303)</b>	<b>Uncontrolled BP (N=24082)</b>	<b>Overall (N=67385)</b>
No	28943 (66.8%)	16728 (69.5%)	45671 (67.8%)
Yes	14360 (33.2%)	7354 (30.5%)	21714 (32.2%)
<b>Schizophrenia</b>			
No	42726 (98.7%)	23853 (99.0%)	66579 (98.8%)
Yes	577 (1.3%)	229 (1.0%)	806 (1.2%)

362 Comparisons between patients with controlled and uncontrolled BP were assessed using Pearson chi-  
363 square tests for categorical covariates and two-sample t-tests for continuous covariates. All p-values  
364 <0.001

365

366

367

368

369

370

371

372

373


374

375

376

377

378



379

380

381 **Figure 1: Flowchart for the generation of this cross-sectional cohort**


382

383

384

385

386



387

388

389 **Figure 2: Percentage of patients with uncontrolled blood pressure**

390

391

392

393


394

395

396

397

398



399

400

401 **Figure 3: Unadjusted and adjusted odds ratios for uncontrolled blood pressure with respect to**  
 402 **patient characteristics.** \*Odds ratio >1 means a greater likelihood of uncontrolled blood pressure.

403 Models were adjusted for age, sex, income quintiles, smoking status, body mass index, and number of  
 404 visits.

405

406


407

408

409

410

411



412

413

414 **Figure 4: Unadjusted and adjusted odds ratios for uncontrolled blood pressure with respect to**

415 **individual long-term conditions.** \*Odds ratio >1 means a greater likelihood of uncontrolled blood

416 pressure. Models were adjusted for age, sex, income quintiles, smoking status, body mass index, and

417 number of visits.

418

419

420

421

422

423

424

425


426

427

428 **Supplementary data**

429

430 **Figure S1: Directed acyclic graph for the effect of multi-morbidity on blood pressure control**



431

432

433 **Table S1: Unadjusted and adjusted odds ratios for uncontrolled blood pressure with respect to**

434 **patient characteristics**

Type	Contrast	Odds ratios	Upper	Lower	P-value
Unadjusted odds ratios	Total number of primary care visits: 9+ visits v.s. 0-2 visits	0.73827	0.79546	0.68520	<0.001
Unadjusted odds ratios	Total number of primary care visits: 6-8 visits v.s. 0-2 visits	0.78719	0.83093	0.74576	<0.001
Unadjusted odds ratios	Total number of primary care visits: 3-5 visits v.s. 0-2 visits	0.80753	0.83877	0.77746	<0.001
Unadjusted odds ratios	Smoking Status: Past v.s. Non Smoker	0.92141	0.96352	0.88113	<0.001
Unadjusted odds ratios	Smoking Status: Current v.s. Non Smoker	1.01420	1.07104	0.96038	0.612
Unadjusted odds ratios	BMI level: 40 or more (Obese Class III) v.s. 18.5 - 24.9	1.20424	1.31402	1.10364	<0.001

ratios	(Normal)				
Unadjusted odds ratios	BMI level: 35 - 39.9 (Obese Class II) v.s. 18.5 - 24.9	1.12685	1.20470	1.05403	<0.001
ratios	(Normal)				
Unadjusted odds ratios	BMI level: 30 - 34.9 (Obese Class I) v.s. 18.5 - 24.9	1.07457	1.13840	1.01432	0.015
ratios	(Normal)				
Unadjusted odds ratios	BMI level: 25 - 29.9 (Overweight) v.s. 18.5 - 24.9	1.03133	1.08717	0.97836	0.251
ratios	(Normal)				
Unadjusted odds ratios	BMI level: 18.4 or less (Underweight) v.s. 18.5 - 24.9	1.11997	1.37281	0.91370	0.275
ratios	(Normal)				
Unadjusted odds ratios	Income Quintiles: 4 v.s. 5	0.98538	1.03246	0.94044	0.536
ratios					
Unadjusted odds ratios	Income Quintiles: 3 v.s. 5	0.97333	1.02475	0.92448	0.303
ratios					
Unadjusted odds ratios	Income Quintiles: 2 v.s. 5	0.97613	1.02786	0.92701	0.359
ratios					
Unadjusted odds ratios	Income Quintiles: 1 v.s. 5	0.97758	1.02763	0.92997	0.373
ratios					
Unadjusted odds ratios	Sex: Male v.s. Female	0.91376	0.94975	0.87915	<0.001
ratios					
Unadjusted odds ratios	Age group: 75-84 years v.s. 85+ years	0.81139	0.86227	0.76352	<0.001
ratios					
Unadjusted odds ratios	Age group: 45-74 years v.s. 85+ years	0.88376	0.94439	0.82703	<0.001
ratios					
Unadjusted odds ratios	Multimorbidity: Yes v.s. No	0.69121	0.71972	0.66384	<0.001
ratios					
Adjusted odds ratios	Total number of primary care visits: 9+ visits v.s. 0-2 visits	0.81565	0.89297	0.74502	<0.001
Adjusted odds ratios	Total number of primary care visits: 6-8 visits v.s. 0-2 visits	0.82926	0.88645	0.77576	<0.001
Adjusted odds ratios	Total number of primary care visits: 3-5 visits v.s. 0-2 visits	0.81522	0.85468	0.77759	<0.001
Adjusted odds ratios	Smoking Status: Past v.s. Non Smoker	0.93085	0.97948	0.88463	0.006
Adjusted odds ratios	Smoking Status: Current v.s. Non Smoker	1.14532	1.22043	1.07484	<0.001
Adjusted odds ratios	BMI level: 40 or more (Obese Class III) v.s. 18.5 - 24.9	1.33611	1.47065	1.21388	<0.001
	(Normal)				
Adjusted odds ratios	BMI level: 35 - 39.9 (Obese Class II) v.s. 18.5 - 24.9	1.23587	1.34055	1.13938	<0.001
	(Normal)				
Adjusted odds ratios	BMI level: 30 - 34.9 (Obese Class I) v.s. 18.5 - 24.9	1.15571	1.23387	1.08249	<0.001



	(Normal)				
Adjusted odds ratios	BMI level: 25 - 29.9 (Overweight) v.s. 18.5 - 24.9	1.08476	1.15337	1.02024	0.009
	(Normal)				
Adjusted odds ratios	BMI level: 18.4 or less (Underweight) v.s. 18.5 - 24.9	1.03778	1.32207	0.81462	0.764
	(Normal)				
Adjusted odds ratios	Income Quintiles: 4 v.s. 5	0.96900	1.03199	0.90985	0.327
Adjusted odds ratios	Income Quintiles: 3 v.s. 5	0.96202	1.02630	0.90176	0.241
Adjusted odds ratios	Income Quintiles: 2 v.s. 5	0.98320	1.04831	0.92213	0.604
Adjusted odds ratios	Income Quintiles: 1 v.s. 5	1.00317	1.06821	0.94208	0.921
Adjusted odds ratios	Sex: Male v.s. Female	0.89949	0.93914	0.86152	<0.001
Adjusted odds ratios	Age group: 75-84 years v.s. 85+ years	0.80118	0.87470	0.73384	<0.001
Adjusted odds ratios	Age group: 45-74 years v.s. 85+ years	0.77803	0.84269	0.71832	<0.001
Adjusted odds ratios	Multimorbidity: Yes v.s. No	0.71761	0.75742	0.67990	<0.001

435

436

437 **Table S2: Mean number of primary care visits for patients with and without multi-morbidity**

438

**(annually)**

Mean (standard deviation) number of primary care visits annually	multimorbidity	
	No	Yes
<b>2017</b>	2.14 (2.17)	3.80 (3.44)
<b>2018</b>	2.30 (2.22)	3.88 (3.36)
<b>2019</b>	2.44 (2.19)	3.91 (3.28)
Frequency (N, column %)		
<b>2017</b>		
<b>0-2 visits</b>	8599	22134

	65.91	40.73
<b>3-5 visits</b>	3523	19794
	27.00	36.43
<b>6-8 visits</b>	729	7838
	5.59	14.42
<b>9+ visits</b>	196	4572
	1.50	8.41
<b>2018</b>		
<b>0-2 visits</b>	8219	21141
	63.00	38.91
<b>3-5 visits</b>	3813	20635
	29.23	37.98
<b>6-8 visits</b>	779	8143
	5.97	14.99
<b>9+ visits</b>	236	4419
	1.81	8.13
<b>2019</b>		
<b>0-2 visits</b>	7934	20688
	60.81	38.07

<b>3-5 visits</b>	4024	21156
	30.84	38.93
<b>6-8 visits</b>	846	8145
	6.48	14.99
<b>9+ visits</b>	243	4349
	1.86	8.00

439

440 **Table S3: Patient characteristics for sub-optimal blood pressure control ( $\geq 130/80$  mmHg)**

	Controlled BP (N=19535)	Uncontrolled BP (N=47850)	Overall (N=67385)	P-value
<b>Age (years)</b>				
Mean (SD)	72.1 (11.5)	69.2 (11.9)	70.1 (11.8)	<0.001
Median [Min, Max]	72.0 [47.0, 111]	69.0 [47.0, 110]	70.0 [47.0, 111]	
<b>Age group (years)</b>				
45-74 years	12809 (65.6%)	35009 (73.2%)	47818 (71.0%)	<0.001
75-84 years	4597 (23.5%)	8816 (18.4%)	13413 (19.9%)	
85+ years	2129 (10.9%)	4025 (8.4%)	6154 (9.1%)	
<b>Sex</b>				
Female	10183 (52.1%)	25586 (53.5%)	35769 (53.1%)	0.00652
Male	9352 (47.9%)	22264 (46.5%)	31616 (46.9%)	
<b>Income Quintiles</b>				
1 (low income)	4259 (21.8%)	9815 (20.5%)	14074 (20.9%)	<0.001
2	3605 (18.5%)	8535 (17.8%)	12140 (18.0%)	

	Controlled BP (N=19535)	Uncontrolled BP (N=47850)	Overall (N=67385)	P-value
3	3223 (16.5%)	7979 (16.7%)	11202 (16.6%)	
4	3323 (17.0%)	8426 (17.6%)	11749 (17.4%)	
5 (high income)	4626 (23.7%)	12043 (25.2%)	16669 (24.7%)	
Missing	499 (2.6%)	1052 (2.2%)	1551 (2.3%)	
<b>Multimorbidity</b>				
No	2528 (12.9%)	10519 (22.0%)	13047 (19.4%)	<0.001
Yes	17007 (87.1%)	37331 (78.0%)	54338 (80.6%)	
<b>Body mass index level</b>				
Missing	3347 (17.1%)	9502 (19.9%)	12849 (19.1%)	<0.001
18.4 or less (Underweight)	152 (0.8%)	260 (0.5%)	412 (0.6%)	
18.5 - 24.9 (Normal)	3226 (16.5%)	6447 (13.5%)	9673 (14.4%)	
25 - 29.9 (Overweight)	6190 (31.7%)	14279 (29.8%)	20469 (30.4%)	
30 - 34.9 (Obese Class I)	4043 (20.7%)	10330 (21.6%)	14373 (21.3%)	
35 - 39.9 (Obese Class II)	1630 (8.3%)	4360 (9.1%)	5990 (8.9%)	
40 or more (Obese Class III)	947 (4.8%)	2672 (5.6%)	3619 (5.4%)	
<b>Most recent smoking status</b>				
Missing	4935 (25.3%)	12867 (26.9%)	17802 (26.4%)	<0.001
Current	1909 (9.8%)	4852 (10.1%)	6761 (10.0%)	
Non Smoker	8856 (45.3%)	22011 (46.0%)	30867 (45.8%)	
Past	3835 (19.6%)	8120 (17.0%)	11955 (17.7%)	
<b>Cancer</b>				
No	16955 (86.8%)	42275 (88.3%)	59230 (87.9%)	<0.001
Yes	2580 (13.2%)	5575 (11.7%)	8155 (12.1%)	
<b>Ischemic Heart disease</b>				
No	16032 (82.1%)	42829 (89.5%)	58861 (87.4%)	<0.001

	<b>Controlled BP</b> <b>(N=19535)</b>	<b>Uncontrolled BP</b> <b>(N=47850)</b>	<b>Overall</b> <b>(N=67385)</b>	<b>P-value</b>
Yes	3503 (17.9%)	5021 (10.5%)	8524 (12.6%)	
<b>Heart failure</b>				
No	18006 (92.2%)	45830 (95.8%)	63836 (94.7%)	<0.001
Yes	1529 (7.8%)	2020 (4.2%)	3549 (5.3%)	
<b>Atrial fibrillation</b>				
No	16799 (86.0%)	43441 (90.8%)	60240 (89.4%)	<0.001
Yes	2736 (14.0%)	4409 (9.2%)	7145 (10.6%)	
<b>Diabetes Mellitus</b>				
No	11842 (60.6%)	33494 (70.0%)	45336 (67.3%)	<0.001
Yes	7693 (39.4%)	14356 (30.0%)	22049 (32.7%)	
<b>Chronic Kidney disease</b>				
No	15193 (77.8%)	40120 (83.8%)	55313 (82.1%)	<0.001
Yes	4342 (22.2%)	7730 (16.2%)	12072 (17.9%)	
<b>Chronic Obstructive Pulmonary Disease</b>				
No	17487 (89.5%)	44075 (92.1%)	61562 (91.4%)	<0.001
Yes	2048 (10.5%)	3775 (7.9%)	5823 (8.6%)	
<b>Mental health</b>				
No	11804 (60.4%)	30997 (64.8%)	42801 (63.5%)	<0.001
Yes	7731 (39.6%)	16853 (35.2%)	24584 (36.5%)	

441

442

443

444 **Table S4: Adjusted odds ratios using GEE model for sensitivity analysis using  $\geq 130/80$  mmHg as**  
 445 **the threshold for sub-optimal blood pressure control.**

Contrast	Adjusted odds ratios	Lower	Upper	P-value
Multimorbidity: Yes vs. No	0.56	0.54	0.59	<0.001
Age group: 45-74 years vs. 85+ years	1.29	1.22	1.37	<0.001
Age group: 75-84 years vs. 85+ years	0.98	0.92	1.05	0.582
Sex: Male vs. Female	0.91	0.88	0.94	<0.001
Income Quintiles: 1 vs. 5	0.93	0.88	0.98	0.005
Income Quintiles: 2 vs. 5	0.95	0.90	1.00	0.062
Income Quintiles: 3 vs. 5	0.97	0.92	1.02	0.34
Income Quintiles: 4 vs. 5	0.98	0.93	1.03	0.405
Region: Urban vs. Rural	0.84	0.78	0.90	<0.001

446

447

448

449 **Table S5: Unadjusted and adjusted odds ratios for uncontrolled blood pressure with respect to co-**

450 **morbidities**

451

Type	Contrast	Odd ratios	Lower	Upper	P-Value
Unadjusted odds ratios	Ischemic Heart Disease: Yes vs. No	0.66969	0.63707	0.70399	<0.001
Unadjusted odds ratios	Heart Failure: Yes vs. No	0.71025	0.65731	0.76745	<0.001
Unadjusted odds ratios	Atrial Fibrillation: Yes vs. No	0.79316	0.75169	0.83692	<0.001
Unadjusted odds ratios	Diabetes Mellitus: Yes vs. No	0.73233	0.70360	0.76223	<0.001
Unadjusted odds ratios	Chronic Obstructive Pulmonary Disease: Yes vs. No	0.82250	0.77670	0.87100	<0.001
Unadjusted odds ratios	Chronic Kidney Disease: Yes vs. No	0.90107	0.86078	0.94326	<0.001
Unadjusted odds ratios	Osteoarthritis: Yes vs. No	0.88485	0.85331	0.91755	<0.001
Unadjusted odds ratios	Cancer: Yes vs. No	0.88660	0.84844	0.92646	<0.001
Unadjusted odds ratios	Dementia: Yes vs. No	0.85688	0.80274	0.91466	<0.001
Unadjusted odds ratios	Depression and/or Anxiety: Yes vs. No	0.87679	0.84454	0.91028	<0.001
Unadjusted odds ratios	Schizophrenia: Yes vs. No	0.78581	0.67154	0.91952	<0.001

<b>Adjusted odds ratios</b>	Ischemic Heart Disease: Yes vs. No	0.73727	0.68770	0.79041	<0.001
<b>Adjusted odds ratios</b>	Heart Failure: Yes vs. No	0.81404	0.72606	0.91268	<0.001
<b>Adjusted odds ratios</b>	Atrial Fibrillation: Yes vs. No	0.92968	0.86071	1.00417	0.064
<b>Adjusted odds ratios</b>	Diabetes Mellitus: Yes vs. No	0.73368	0.70013	0.76885	<0.001
<b>Adjusted odds ratios</b>	Chronic Obstructive Pulmonary Disease: Yes vs. No	0.98163	0.90611	1.06344	0.65
<b>Adjusted odds ratios</b>	Chronic Kidney Disease: Yes vs. No	0.94286	0.88606	1.00330	0.063
<b>Adjusted odds ratios</b>	Osteoarthritis: Yes vs. No	0.88625	0.84715	0.92716	<0.001
<b>Adjusted odds ratios</b>	Cancer: Yes vs. No	0.95232	0.89199	1.01672	0.143
<b>Adjusted odds ratios</b>	Dementia: Yes vs. No	0.86759	0.79505	0.94675	0.001
<b>Adjusted odds ratios</b>	Depression and/or Anxiety: Yes vs. No	0.90557	0.86453	0.94856	<0.001
<b>Adjusted odds ratios</b>	Schizophrenia: Yes vs. No	0.79424	0.65170	0.96795	0.022

452

453

454

455

456

## 457 **Appendix**

458 The appendix section contains the following sections:

459 i) Drug names for different classes of hypertension medications;

460 ii) Definition for the hypertension phenotype;

461 iii) Definition for primary care visit in UTOPIAN database;

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478 **Hypertension medication classes**

479 The following search criteria were used to identify hypertension medication:

<b>Drug class name</b>	<b>Search criteria</b>
<b>ACE inhibitors</b>	%medication(in=ACE,  search='benazepril Lotensin captopril Capoten Captotec Captril cilazapril Inhib ace Inhibase enalapril Vasotec fosinopril Monopril lisinopril Zestril Prinivil per indopril Coversyl quinapril



	hcl Accupril Accupro ramipril Altace trandolapril Mavik');  
<b>ARB inhibitors</b>	%medication(in=ARB,  search='candesartan Atacand eprosartan Teveten irbesartan Avapro losartan Cozaar olmesartan Olmetec telmisartan Micardis valsartan Diovan');  
<b>Calcium channels</b>	%medication(in=Ca_channel,  search='amlodipine Norvasc diltiazem Cardizem Tiazac felodipine Renedil Plendil nicardipine Cardene nifedipine Adalat nimodipine Minotop verapamil Isopstin Veralan Veramil');  
<b>Beta-blockers</b>	%medication(in=beta_blockers,  search='acebutolol Monitan Sectral Rhotral atenolol Tenormin bisoprolol Monocor labetalol Trandate metoprolol Lopressor Toprol Betaloc nadolol Corgard oxprenolol Trasicor pindolol Visken propranolol Inderal Detensol');  
<b>Diuretics</b>	%medication(in=diuretics,  search='amiloride Midamor spironolactone Aldactone triamterene NeoDiurex chlortalidone Thiazide Hygroton hydrochlorothiazide Oretic Microzide

	<p>Diuchlor H Esidrix Hydro Aquil Hydrodiuril Neo Codema Urozide Apo-Hydro indapamide Lozide');</p>
<p><b>Other classes of hypertension medication</b></p>	<p>*****</p> <p>Others includes</p> <ul style="list-style-type: none"> <li>- Renin Inhibitor</li> <li>- Alpha-2 Adrenergic Receptor Agonist</li> <li>- combination medications</li> </ul> <p>*****;</p> <p>%medication(in=others,</p> <p>search=</p> <p>'aliskiren Basilez clonidine Catapres Catapresan Kapvay Dixarit methyldopa Dopazide Methazide Doparil benazepril &amp; hydrochlorothiazide Lotensin cilazapril &amp; hydrochlorothiazide Inhibace Plus enalapril &amp; hydrochlorothiazide Vaseretic ramipril &amp; hydrochlorothiazide Altace HCT lisinopril &amp; hydrochlorothiazide Zestoretic Prinzide perindopril &amp; indapamide Coversyl Plus perindopril &amp; amlodipine Viacoram </p>

quinapril & hydrochlorothiazide Accuretic
amlodipine & telmisartan Twynsta
azilsartan & chlortalidone Edarbyclor
eprosartan & hydrochlorothiazide Teveten Plus
candesartan & hydrochlorothiazide Atacand Plus
hydrochlorothiazide & irbesartan Avalide
hydrochlorothiazide & losartan Hyzaar
hydrochlorothiazide & olmesartan Benicar HCT Olmetec Plus
valsartan & hydrochlorothiazide Diovan HCT
losartan & hydrochlorothiazide Hyzaar
telmisartan & hydrochlorothiazide Micardis HCT Micardis Plus
valsartan & sacubitril Entresto
atenolol & chlortalidone Tenoretic
atenolol & hydrochlorothiazide
felodipine & metoprolol Logimat Mibloc Mobloc Logimax Forte Mobloc Forte
nadolol & bendroflumethiazide Corzide
pindolol & hydrochlorothiazide Viskazide
propranolol & hydrochlorothiazide Inderide
timolol & hydrochlorothiazide Timolide
felodipine & ramipril Inotens Unimest And Unitens

verapamil & trandolapril   Tarka
chlortalidone & reserpine   Regroton
methyldopa & hydrochlorothiazide   Aldoclor   Aldoril
clonidine & chlortalidone   Clorpres   Combipres
reserpine & hydrochlorothiazide   Hydroserpine   Hydropres   Serpasil Esidrix
reserpine & hydrochlorothiazide   hydralazine hcl Ser-Ap-ES   Serpazide   Uni Serp   Hydrap-Es   Diuretic-Ap-Es   Marpres   Serathide   Unipres   Serpex
metoprolol & hydrochlorothiazide   Dutoprol   Lopressor HCT
metoprolol & chlortalidone   Lopressidone   Logroton
amiloride & hydrochlorothiazide   Amiloride HCTZ   Amihydro   Riva- Amilzide   Amilazide   Amilzide   Atenidone   Moduretic
spironolactone & hydrochlorothiazide   Aldactazide   Spirozide   Spirozine
triamterene & hydrochlorothiazide   Dyazide   Maxzide   Diazide   Pro Triazide   Triamzide   Riva-Zide   Triazide   Hydro-Triam');

480

481

482

483 **Hypertension phenotype**

484

485 We defined the hypertension phenotype using the following criteria:

486 1. Free text documentation of hypertension in the past or present health condition section of  
487 the cumulative patient included at least one of the following terms:

488	Include	Do not include
489	Hypertension	Hypertensive response
490	Hypertensive	Borderline
491	Htn	Occular/ocular
492		Maternal
493		Gestation
494		White coat
495		Pulmonary
496		Pregnancy induced/PIH

497 2. Anti-hypertensive medication (listed above) was prescribed and an elevated blood pressure  
498 reading was recorded at any point in the EMR

499 a. elevated blood pressure reading is defined as systolic blood pressure  $\geq$  140 mmHg or  
500 diastolic blood pressure  $\geq$  90 mmHg

501 OR

502 3. Anti-hypertensive medication (listed above) was prescribed and a billing record with the  
503 diagnosis code for hypertension (401) was found at any point in the EMR

504 OR

505 4. A billing record with the diagnosis code for hypertension (401) was found and an elevated  
 506 blood pressure reading was recorded at any point in the EMR

507 a. elevated blood pressure reading is defined as systolic blood pressure  $\geq$  140 mmHg or  
 508 diastolic blood pressure  $\geq$  90 mmHg

509

510 **Definition for primary care visit in UTOPIAN database**

511 OHIP service codes billed during the study period (Jan 2017 to Dec 2019) were used to select family  
 512 physician visits that occurred via telephone, video, or in-person. Billing records for eligible patients  
 513 containing any of the following service codes were counted as family physician visits:

Code	Description	Code	Description
A001	minor assessment	K017	periodic health visit-child aft. 2nd birthday
A002	enhanced 18-month well baby visit	K022	hiv prim care individ care 1/2 hr or major part
A003	major assessment	K028	sexually transmitted disease (std) counseling
A004	general re-assessment	K030	diabetic management fee
A007	intermediate assessment	K032	gp-specific neurocognitive assessment
A008	mini assessment	K033	counselling - 1 pt/yr/unit
A071	complex medical specific re-assessment	K039	smoking cessation follow-up visit
A131	complex medical specific re-assessment	K130	periodic health visit - adolescent

A134	medical specific re-assessment	K131	periodic health visit - adult aged 18 to 64 inclusive
A624	medical specific re-assessment	K132	periodic health visit - adult 65 years of age and older
A888	partial assessment	K680	substance abuse - extended assessment
A903	pre-op assessment	P003	obs.-prenatal care-gen.assess-major prenatal visit
A920	medical management of early pregnancy, initial visit	P004	obs.-prenatal care-minor prenatal assess.-subseq.prenat.vis.
K005	primary mental health	P005	antenatal health screen
K007	ind. psychotherapy per half hour - gp	P008	obs.-post-natal care in office
K013	counselling-one or more people-per 1/2hr	K037	fibromyalgia/chronic fatigue syndrome care
K080	Minor assessment of patient by telephone or video	K081	Intermediate assessment including psychotherapy by telephone or video
K082	Psychotherapy, psychiatric or mental health counselling by telephone or video	K087	Minor assessment of an uninsured by telephone or video
K088	Intermediate assessment of an uninsured patient including psychotherapy by telephone or video	K089	Psychotherapy, psychiatric or mental health counselling of an uninsured patient by telephone or video

514

515

516

